Abstract
OBJECTIVE: To evaluate the short-term fluorescein angiographic and visual acuity effects of a single intravitreal injection of bevacizumab (Avastin) for the management of persistent new vessels (NV) associated with diabetic retinopathy. METHODS: A prospective, nonrandomized open-label study of diabetic patients with actively leaking NV refractory to laser treatment and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) worse than 20/40. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 (±1) following intravitreal injection of 1.5 mg of bevacizumab. Main outcome measures include changes in total area of fluorescein leakage from active NV and BCVA. RESULTS: Fifteen consecutive patients (men, 9 [60%]; women, 6 [40%]) were included and all completed the 12-week follow-up period of the study. The mean ± SD age of participants was 60.08 ± 7.75 years (median, 59.5; range, 49-73 years). At baseline, mean ± standard error of the mean (SEM) NV leakage area was 27.79 ± 6.29 mm. The mean ± SEM area of active leaking NV decreased significantly to 5.43 ± 2.18 mm and 5.50 ± 1.24 mm (P < 0.05, Tukey multiple comparisons post-test) at 1 and 12 weeks postinjection, respectively; at week 6 no leakage was observed. The mean ± SEM logMAR (Snellen equivalent) BCVA improved significantly from 0.90 (20/160) ± 0.11 at baseline to 0.76 (20/125) ± 0.12, 0.77 (20/125) ± 0.11, and 0.77 (20/125) ± 0.12 at weeks 1, 6, and 12, respectively (P < 0.05, Tukey multiple comparisons post-test). No major adverse events were observed. CONCLUSIONS: Intravitreal injection of bevacizumab achieved short-term reduction of fluorescein leakage from persistent active NV without loss of vision in patients with diabetic retinopathy. Further studies to investigate the role of anti-VEGF therapy with bevacizumab for the management of diabetic retinopathy refractory to laser treatment are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1006-1013 |
| Number of pages | 8 |
| Journal | Retina |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| State | Published - Nov 1 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Ophthalmology
Cite this
}
Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (Ibepe study). / Jorge, Rodrigo; Costa, Rogério A.; Calucci, Daniela; Cintra, Léssia P.; Scott, Ingrid.
In: Retina, Vol. 26, No. 9, 01.11.2006, p. 1006-1013.Research output: Contribution to journal › Article
TY - JOUR
T1 - Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (Ibepe study)
AU - Jorge, Rodrigo
AU - Costa, Rogério A.
AU - Calucci, Daniela
AU - Cintra, Léssia P.
AU - Scott, Ingrid
PY - 2006/11/1
Y1 - 2006/11/1
N2 - OBJECTIVE: To evaluate the short-term fluorescein angiographic and visual acuity effects of a single intravitreal injection of bevacizumab (Avastin) for the management of persistent new vessels (NV) associated with diabetic retinopathy. METHODS: A prospective, nonrandomized open-label study of diabetic patients with actively leaking NV refractory to laser treatment and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) worse than 20/40. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 (±1) following intravitreal injection of 1.5 mg of bevacizumab. Main outcome measures include changes in total area of fluorescein leakage from active NV and BCVA. RESULTS: Fifteen consecutive patients (men, 9 [60%]; women, 6 [40%]) were included and all completed the 12-week follow-up period of the study. The mean ± SD age of participants was 60.08 ± 7.75 years (median, 59.5; range, 49-73 years). At baseline, mean ± standard error of the mean (SEM) NV leakage area was 27.79 ± 6.29 mm. The mean ± SEM area of active leaking NV decreased significantly to 5.43 ± 2.18 mm and 5.50 ± 1.24 mm (P < 0.05, Tukey multiple comparisons post-test) at 1 and 12 weeks postinjection, respectively; at week 6 no leakage was observed. The mean ± SEM logMAR (Snellen equivalent) BCVA improved significantly from 0.90 (20/160) ± 0.11 at baseline to 0.76 (20/125) ± 0.12, 0.77 (20/125) ± 0.11, and 0.77 (20/125) ± 0.12 at weeks 1, 6, and 12, respectively (P < 0.05, Tukey multiple comparisons post-test). No major adverse events were observed. CONCLUSIONS: Intravitreal injection of bevacizumab achieved short-term reduction of fluorescein leakage from persistent active NV without loss of vision in patients with diabetic retinopathy. Further studies to investigate the role of anti-VEGF therapy with bevacizumab for the management of diabetic retinopathy refractory to laser treatment are warranted.
AB - OBJECTIVE: To evaluate the short-term fluorescein angiographic and visual acuity effects of a single intravitreal injection of bevacizumab (Avastin) for the management of persistent new vessels (NV) associated with diabetic retinopathy. METHODS: A prospective, nonrandomized open-label study of diabetic patients with actively leaking NV refractory to laser treatment and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) worse than 20/40. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 6, and 12 (±1) following intravitreal injection of 1.5 mg of bevacizumab. Main outcome measures include changes in total area of fluorescein leakage from active NV and BCVA. RESULTS: Fifteen consecutive patients (men, 9 [60%]; women, 6 [40%]) were included and all completed the 12-week follow-up period of the study. The mean ± SD age of participants was 60.08 ± 7.75 years (median, 59.5; range, 49-73 years). At baseline, mean ± standard error of the mean (SEM) NV leakage area was 27.79 ± 6.29 mm. The mean ± SEM area of active leaking NV decreased significantly to 5.43 ± 2.18 mm and 5.50 ± 1.24 mm (P < 0.05, Tukey multiple comparisons post-test) at 1 and 12 weeks postinjection, respectively; at week 6 no leakage was observed. The mean ± SEM logMAR (Snellen equivalent) BCVA improved significantly from 0.90 (20/160) ± 0.11 at baseline to 0.76 (20/125) ± 0.12, 0.77 (20/125) ± 0.11, and 0.77 (20/125) ± 0.12 at weeks 1, 6, and 12, respectively (P < 0.05, Tukey multiple comparisons post-test). No major adverse events were observed. CONCLUSIONS: Intravitreal injection of bevacizumab achieved short-term reduction of fluorescein leakage from persistent active NV without loss of vision in patients with diabetic retinopathy. Further studies to investigate the role of anti-VEGF therapy with bevacizumab for the management of diabetic retinopathy refractory to laser treatment are warranted.
UR - http://www.scopus.com/inward/record.url?scp=33749631288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749631288&partnerID=8YFLogxK
U2 - 10.1097/01.iae.0000246884.76018.63
DO - 10.1097/01.iae.0000246884.76018.63
M3 - Article
C2 - 17151487
AN - SCOPUS:33749631288
VL - 26
SP - 1006
EP - 1013
JO - Retina
JF - Retina
SN - 0275-004X
IS - 9
ER -